Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Surcinelli Andrea, Kalincik Tomas, Roos Izanne, D'Amico Emanuele, Lechner-Scott Jeannette, Ozakbas Serkan, Hradilek Pavel, Horáková Dana, Vachova Marta, Panzera Ivan, Ruzza Stefano, Piscaglia Maria Grazia, Gerlach Oliver, Meca-Lallana Jose Eustasio, Valero-López Gabriel, Kermode Allan G, Fabis-Pedrini Marzena J, Prevost Julie, Ampapa Radek, Hodgkinson Suzanne, Grand'Maison Francois, Khoury Samia J, John Nevin A, Peterka Marek, Houskova Jana, Recmanova Eva, Rous Zuzana, Shaygannejad Vahid, Alroughani Raed, Kuhle Jens, Jakob Gregor Brecl, Grammond Pierre, Patti Francesco, Van der Walt Anneke, Butzkueven Helmut, Foschi Matteo
Аннотация
OBJECTIVES: To compare clinical outcomes of anti-CD20 monoclonal antibodies and sphingosine-1-phosphate receptor modulators (S1PRMs) in LOMS.
DESIGN: Multicentre, observational cohort study based on real-world data from an international multiple sclerosis registry.
METHODS: We analysed data from the MSBase registry, including relapsing-remitting LOMS patients treated with anti-CD20 therapies (ocrelizumab, ofatumumab, rituximab) or S1PRMs (fingolimod, ozanimod, siponimod, ponesimod) for ⩾6 months. Primary outcomes were annualised relapse rate (ARR), Expanded Disability Status Scale (EDSS) change, confirmed disability worsening (CDW), progression independent of relapse activity (PIRA), and PIRA without MRI activity (PIRMA). Analyses used inverse probability of treatment weighting (IPTW). Causal forest and best linear projector (BLP) models explored effect modification.
RESULTS: After weighting, 347 patients (median age 53.7 years; 69% female; median follow-up 6.9 years) were included. No significant differences were found for ARR, EDSS change, CDW, PIRA, or PIRMA. Exploratory analyses suggested greater anti-CD20 benefit in patients with earlier onset (⩽55 years), shorter disease duration (⩽2 years from diagnosis), and lower disability (EDSS < 3).
CONCLUSIONS: In this real-world LOMS cohort, no statistically significant differences were observed between anti-CD20 and S1PRM therapies. Exploratory analyses suggested anti-CD20 may be associated with better outcomes in selected subgroups; these findings are hypothesis-generating.
TRIAL REGISTRATION: Not applicable.